Primeri uporabe See tables v Angleški in njihovi prevodi v Slovenski
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Official/political
-
Programming
See tables 2 and 3 in section 3.2.1.
The dose depends on the patient's bodyweight(see tables below).
(See tables in the text of the opinion.).
As regards negative developments(see Tables 1 and 2 in the Appendix):.
See Tables 1 and 2 for more information.
Doses should beadjusted for significant changes in body weight(see Tables 2 and 3).
(4) See Tables DUP-3 and DUP-4 in the 2006 statistical bulletin.
The recommended dose titration for children andadolescents is provided below(see tables 1 and 2).
(see tables in Annexes V and VI for full explanation).
The industry also reduced significantly its costs(see Tables 8a and 8b above) and improved its capacity utilisation.
(3) See Tables DUP-2 and DUP-5 in the 2006 statistical bulletin.
Positive developments highlighted by the report for the period between 2000 and the present day(see Tables 1 and 2 in the Appendix) include:.
See Tables PPP-2 and PPP-6 in the 2007 statistical bulletin.
Votes on GM food andfeed continue to systematically lead to“no opinion”(see Tables 2 and 3 and Graph 1 of the Annex).
See Tables GPS-4 and GPS-15 in the 2007 statistical bulletin.
The management of adverse reactions may require dose reduction,treatment interruption or treatment discontinuation(see Tables 1 and 2).
See Tables SZR-11 and SZR-12 in the 2007 statistical bulletin.
The management of adverse reactions may require treatment interruption, dose reduction,or treatment discontinuation(see Tables 1 and 2).
See Tables HSR-7, HSR-9 and HSR-11 in the 2007 statistical bulletin.
Treatment with vemurafenib should continue until disease progression orthe development of unacceptable toxicity(see tables 1 and 2 below).
See Tables TDI-10, TDI-11 and TDI-102 to TDI-109 in the 2007 statistical bulletin.
Mirabegron demonstrated statistically significant larger improvements compared to placebo for both co-primaryendpoints as well as secondary endpoints(see Tables 1 and 2).
For more information see Tables PDU-1, PDU-2 and PDU-3 in the 2006 statistical bulletin.
Management of adverse drug reactions or QTc prolongation may require dose reduction,temporary interruption and/or treatment discontinuation(see tables 1 and 2).
See Tables TDI-13, TDI-14 and TDI-21(part i) and(part ii) in the 2007 statistical bulletin.
The macroeconomic scenario appears to be plausible until2008 and mildly favourable thereafter(see tables attached for growth and budgetary projections of the countries concerned).
See Tables TDI-4, TDI-5(part ii), TDI-24, TDI-116 and TDI-117 in the 2007 statistical bulletin.
For more information see Tables PDU-1, PDU-2 and PDU-3 in the 2006 statistical bulletin. Sources: National focal points.
See Tables GPS-17, GPS-18 and GPS-19 and Figures GPS-1, GPS-3, GPS-7 and GPS-12 in the 2007 statistical bulletin.
For more information, see Tables PDU-1, PDU-2 and PDU-3 in the 2007 statistical bulletin. Sources: National focal points.